In this episode of Petri Dish Perspectives: Biotech Unleashed, we journey through the 165+ year saga of Bristol Myers Squibb (BMS) — from 19th-century Brooklyn apothecaries and sparkling laxatives 💊 to cutting-edge CAR-T therapies and checkpoint inhibitors in cancer treatment 🧫🔥.
Host Manead, a PhD scientist in cancer biology and analytical chemistry, breaks down:
📜 The parallel founding stories of E.R. Squibb & Sons and Bristol-Myers
🧠 The game-changing 1989 merger that created BMS
❤️ Blockbuster hits in cardiovascular health (Plavix, anyone?)
🧪 The leap into immuno-oncology with Opdivo and Yervoy
🧲 The bold $74B acquisition of Celgene — and how it supercharged BMS’s cell therapy pipeline
🚀 What’s next in AI-driven R&D, off-the-shelf CAR-Ts, and more
If you’re curious how a legacy pharma reinvented itself into an oncology and biotech juggernaut, this episode is for you.
Grab your favorite drink and tune in to explore the science, the strategy, and the standout leaders behind BMS.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#PetriDishPerspectives #BiotechUnleashed #BMS #Immunotherapy #CAR_T #PharmaHistory #Oncology #BiotechPodcast
© 2025 Petri Dish Perspectives LLC. All rights reserved.
